INTRODUCTION
We and others have found in experiments in rabbits and rats that repeated vessel injury caused by indwelling aortic catheters shortens platelet survival (1) (2) (3) (4) .' In other experiments we have shown that the reduction of platelet survival cannot be solely attributed to platelet accumulation in thrombi associated with the damaged vessel wall or catheters but seems to be related at least in part to the extent of vessel wall injury and platelet interaction with the damaged vessel wall.' Exposure of platelets to ADP, thrombin, or thromboxane A2 with which platelets are likely to come in contact during thrombus formation, does not shorten platelet survival (5, 6) . However, proteolytic enzymes that cleave platelet membrane glycoproteins do shorten platelet survival (7) . Thus, a possible mechanism by which the damaged vessel wall might modify platelets and shorten platelet survival is through the local activation of plasmin or other proteolytic enzymes; these enzymes could modify the platelets associated with the damaged wall so that when the platelets are lost from the injury site they are cleared from the circulation. To determine whether local activation of the fibrinolytic mechanism might be involved in shortened platelet survival, we have examined the effect of the antifibrinolytic agent i-aminocaproic acid (EACA)2 on shortened platelet survival induced by indwelling aortic catheters in rats.
METHODS
Platelet survival studies. Suspensions of twice washed platelets were prepared from blood obtained from the exposed hearts of several Wistar rats anesthetized with ether (8) .' The platelets were labeled with Na2 5lCrO4 (100 -400 mCi/mg Cr; Amersham/Searle, Arlington Heights, IL; 50 MCi/rat) in the first washing solution, washed once in calcium-free Tyrode's solution and suspended at a concentration of 1.5-2.5 X 109 platelets/ml in the same plasma from which the platelets had been prepared. The labeled platelets ' Winocour, P. D., M. Cattaneo, D. Somers, M. Richardson, R. L. Kinlough-Rathbone, and J. F. Mustard. Submitted for publication. 2 Abbreviation used in this paper: EACA, E-aminocaproic acid.
(1 ml) were injected through a 27G needle into a superficial penile vein of rats anesthetized with ether. The radioactivity of samples (100 ,l) of the platelet suspension was determined in a gamma counter and the total amount of radioactivity injected into each rat was calculated. Samples of blood were taken into heparinized micro-hematocrit tubes (DADE Division, American Hospital Supply Corporation, Miami, FL) from freshly cut ends of the tails of rats anesthetized with ether. Blood samples were centrifuged in a micro-hematocrit centrifuge (International Equipment Company, Needham Heights, MA) and after recording the hematocrits and lengths of the columns of blood, the radioactivity of the sample was determined in a gamma counter. Using the weight of known lengths of water in a number of microhematocrit tubes, a standard diameter of the tubes was established. Knowing the length of the column of blood collected and the radioactivity of the sample, the radioactivity of each sample per milliliter of blood was calculated. The labeled platelets were injected into the rats 18 h before the catheter was introduced. The first blood sample, taken just before the catheter was introduced, was assigned a value of 100%. Blood samples were taken 3, 6, 9 , and 11 h after insertion of the catheter. Radioactivity in the samples was determined and the mean platelet life span was calculated from the radioactivity in individual samples using the gamma function described by Murphy and Bolling (9) Control animals had their femoral artery exposed and ligated in a "sham operation." Surgery was performed immediately after the first blood sample was taken.
11 h after a sham operation or insertion of the catheters, the animals were given an injection of heparin (500 U/kg intravenously; Hepalean, Harris Laboratories, Brantford, Ontario) and exsanguinated from the exposed heart under ether anesthesia. The aorta at the aortic arch and left femoral artery were both cut and blood was removed from the aorta by washing it through with -7 ml of Tyrode's solution containing heparin (5 U/ml). The aortae were removed from the animals, dissected free of extraneous tissue, and cut into segments of -2.5 cm. Each segment was placed in 4% paraformaldehyde in phosphate buffer (2 ml), pH 7 (12) . '25I-Fibrin-coated tubes were prepared, filled with Tyrode's solution containing 0.1% sodium azide, and stored at 40C. Before use, the tubes were washed three times with Tyrode's solution. Blood samples (0.9 ml) were taken into heparin (0.1 ml of 100 U/ml) in triplicate 8 h after starting the treatment, pipetted into '251-fibrin-coated tubes and incubated at 370C for 1 h. After 1 h, Tyrode's solution (2 ml) containing heparin (10 U/ml) was added rapidly to each tube and the contents poured into fresh tubes.
Blood was rinsed from the '251-fibrin-coated tubes with a further 1 ml of Tyrode's solution containing heparin and pooled with the rest of the blood sample. Radioactivity of both tubes was determined in a gamma counter. Radioactivity from both tubes was added together and the radioactivity of the blood in the uncoated tube was expressed as a percentage of the total and considered as the percentage fibrinolysis.
Platelet aggregation. Blood was collected into heparin (10 U/ml) or trisodium citrate (0.31%) 8 h after the EACA treatment was begun and platelet-rich plasma obtained by centrifugation at 1,800 g for 3 min. The platelet count was adjusted to 109 platelets per ml with platelet-poor plasma. Platelet aggregation to ADP, collagen or sodium arachidonate (Sigma Chemical Co) was measured in an aggregometer (Chronolog Corporation, Havertown, PA) (13) . The collagen and sodium arachidonate were prepared as previously described (14, 15) .
Scanning electron microscopy. Sections from the thoracic aortae from two animals in each group were examined by scanning electron microscopy (16) . The extent of fibrin formation on the aorta surface was determined independently by three investigators (who were unaware of the treatment group) by placing a 10-Am grid on each micrograph and recording the presence or absence of fibrin strands on each 10 square Am.
RESULTS
In these experiments, the indwelling aortic catheters of the size and type used did not induce macroscopic thrombus formation in rats. EACA at a dose of 1 g/kg every 4 h significantly prolonged the shortened platelet survival observed in animals with the indwelling aortic catheters (Table I) .
The whole blood fibrinolytic activity was significantly reduced in EACA-treated animals. The percentage of '251-fibrin digested by whole blood from placebo-treated rats was 4.5±0.7%, whereas 0.7±0.1% was digested by blood from EACA-treated rats (P < 0.01). (Table I ).
DISCUSSION
The observation that shortened platelet survival in rats with indwelling aortic catheters returns towards normal when rats are given EACA, is in keeping with the hypothesis that proteolytic enzymes, possibly plasmin, may modify platelets that come in contact with the injured vessel wall leading to rapid clearance of these platelets from the circulation when they leave the vessel wall. In other experiments it has been shown that modification of platelet membrane glycoproteins by proteolytic enzymes, such as plasmin, causes their rapid clearance from the circulation (7). Platelet glycoproteins may be involved in platelet adherence to exposed subendothelium (17) . It is possible that local release or activation of proteolytic enzymes by the cells in the vessel wall or proteolytic enzymes released from leukocytes may cleave surface proteins or glycoproteins of platelets adherent to the wall, leading to loss of platelets from the subendothelium and an increased rate of clearance of these altered platelets from the circulation. The EACA-treated animals with indwelling aortic catheters had nearly three times as much 5tCr associated with the surface of the vessel 11 h after insertion of the catheter. Since the amount of 5tCr on the surface is the net radioactivity resulting from platelet loss and platelet accumulation, this increased radioactivity could be a result of decreased loss of platelets from the surface of the vessel wall or increased platelet accumulation at the injury sites.
Evidence that treatment with the antifibrinolytic agent inhibited proteolytic activity was obtained from the observation that extensive deposits of fibrin were found on the vessel wall of some treated animals but were not found in untreated controls. Vessel walls contain plasminogen activator that can be released from the tissues; there do not appear to have been detailed studies of whether the smooth muscle cells of the vessel wall, in addition to the endothelial cells, contain plasminogen activator (18) . Astrup and Buluk (19) examined the fibrinolytic activity of the blood vessels of a number of species and found that in rats the intima and media together did have fibrinolytic activity; these authors were not able to localize this activity more accurately, however. Leukocytes have proteolytic activity and their interaction with the vessel wall may result in the release of additional proteolytic enzymes that could influence platelet interaction with the injured vessel wall (20) .
In studies in man, fibrinolytic therapy was not found to influence platelet survival (21) , although there is some evidence that subjects with cirrhosis of the liver who have increased fibrinolytic activity do show shortened platelet survival (22) . Ordinas et al. (23) have shown that platelets from such patients have altered platelet membrane glycoproteins. It is unlikely that FIGURE 1 Scanning electron micrographs of the injured vessel walls of rats with indwelling aortic catheters. A. Platelets and fibrin on the vessel wall of a rat that had been treated with EACA over an 11-h period before the specimen was prepared. B. A lower magnification of the platelet layer on the aorta of a rat that had received a placebo solution over the 11-h period before the sample was prepared. C. This picture of the vessel wall of a rat that had received a placebo solution over an 11-h period before the specimen was prepared was taken at a higher magnification; no fibrin is apparent on the surface. plasmin formed by activation of plasminogen in plasma would have a significant effect on the platelets because plasmin would be rapidly neutralized by the normal inhibitors in plasma (24) . However, activation of plasmin or other proteolytic enzymes on the surface of the vessel where the platelets are in contact with the wall, could have a localized effect on the platelets. In earlier experiments, Niewiarowski et al. (25) found that the infusion of high concentrations of streptokinase into rabbits altered platelet function and shortened platelet survival. Green and associates (26, 27) found that EACA inhibits platelet function and prolongs the bleeding time, raising the possibility that the effects of EACA may be mediated through an effect on platelet function. A number of studies have demonstrated that inhibition of platelet aggregation does not necessarily correlate with shortened platelet survival (28, 29) . Furthermore, at the concentration used in these experiments in rats, EACA did not inhibit platelet function.
If stimulation or injury of the endothelium or the vessel wall does lead to local plasmin formation and the activation of other proteolytic enzymes, platelets that interact at these sites could be altered in such a way that their survival is shortened. If this is the case, then shortened platelet survival may be more a reflection vessel wall injury or stimulation than of thromboembolic events.
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